Impressing analysts with a big Q3, AstraZeneca whisks away the losers in the pipeline
A little more than 2 years after they started a pivotal Phase III study, AstraZeneca and its partners at Chi-Med have officially iced the late-stage, head-to-head study of savolitinib with Sutent in MET-driven cases of papillary renal cell carcinoma. That was one of 6 pipeline programs that ended in the scrap heap in the Q3 cleanup at the pharma giant.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
